Avoid cell-to-cell disease transmission in ALS patient-based cellular model
Efficacy in transgenic TDP-43 mouse model and in ALS patient-based cellular model
Synthesis and first biological profile of the inhibitors
Molefy Pharma launches new website to share breakthrough progress in ALS research and drug development
Santa Cruz de Tenerife, 9 de junio de 2025. Molefy Pharma, a biotech company born from the collaboration between ARQUIMEA and CSIC, has announced the launch of its new corporate website www.molefypharma.com , a platform designed to offer comprehensive insight into the company’s mission, scientific research, and advancements in the development of innovative treatments for […]
Molefy wins the eighth edition of the Investment Forum of the Science and Technology Park of Tenerife
Moley Pharma, a spin-off of the CSIC in collaboration 1with ARQUIMEA dedicated to finding a cure for amyotrophic lateral sclerosis (ALS) through the AP-2 molecule, has won first prize in the eighth edition of the Investment Forum of the Science and Technology Park of Tenerife. The event, held as part of the second edition of Hub Intech, […]
Molefy Pharma Showcased New ALS Research at ENCALS 2025 in Turin
Santa Cruz de Tenerife, 9 de junio de 2025. Molefy Pharma, a biotech company focused on developing innovative therapies for ALS and other neurodegenerative diseases, successfully presented three scientific papers at the ENCALS 2025 Meeting, held in Turin, Italy, reaffirming its commitment to advancing therapeutic innovation in Amyotrophic Lateral Sclerosis (ALS). The European Network to […]